Corcept Therapeutics Inc
CORT71.880USD
-0.130-0.18%
Close 07/11, 16:00（ET）Quotes delayed by 15 min
7.62BMarket Cap
56.85P/E TTM
More Details of Corcept Therapeutics Inc Company
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Company Info
Ticker SymbolCORT
Company nameCorcept Therapeutics Inc
IPO dateApr 15, 2004
Founded at1998
CEODr. Joseph K. Belanoff, M.D.
Number of employees500
Security typeOrdinary Share
Fiscal year-endApr 15
Address101 Redwood Shores Parkway
CityREDWOOD CITY
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94065
Phone16506888803
Websitehttps://www.corcept.com/
Ticker SymbolCORT
IPO dateApr 15, 2004
Founded at1998
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
-1.34%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+5.82%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+54.67%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
107.40K
--
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
35.79K
-4.90%
Mr. Atabak Mokari
Mr. Atabak Mokari
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.06K
+7.91%
Mr. Joseph Douglas Lyon
Mr. Joseph Douglas Lyon
Chief Accounting and Technology Officer
Chief Accounting and Technology Officer
10.07K
--
Mr. William Guyer, Pharm.D.
Mr. William Guyer, Pharm.D.
Chief Development Officer
Chief Development Officer
5.49K
--
Mr. Gregg Huber Alton, J.D.
Mr. Gregg Huber Alton, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
-1.34%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+5.82%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+54.67%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
107.40K
--
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
35.79K
-4.90%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.28%
The Vanguard Group, Inc.
9.39%
Ingalls & Snyder LLC (Asset Management)
7.30%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.01%
Other
60.23%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.28%
The Vanguard Group, Inc.
9.39%
Ingalls & Snyder LLC (Asset Management)
7.30%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.01%
Other
60.23%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
35.90%
Investment Advisor
31.22%
Individual Investor
11.55%
Hedge Fund
8.44%
Research Firm
1.58%
Pension Fund
1.03%
Sovereign Wealth Fund
0.82%
Bank and Trust
0.51%
Family Office
0.06%
Other
8.88%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
722
96.66M
91.15%
-8.10M
2025Q1
746
97.45M
92.10%
-9.12M
2024Q4
673
98.29M
93.20%
-10.89M
2024Q3
625
101.82M
97.42%
-10.51M
2024Q2
589
103.22M
99.09%
-12.69M
2024Q1
582
107.51M
103.94%
+2.98M
2023Q4
555
98.31M
95.40%
-4.22M
2023Q3
540
96.45M
94.14%
-5.68M
2023Q2
523
94.35M
92.83%
-12.18M
2023Q1
528
100.60M
93.30%
-751.20K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
13.02M
12.28%
-611.02K
-4.48%
Mar 31, 2025
The Vanguard Group, Inc.
9.96M
9.39%
-133.66K
-1.32%
Mar 31, 2025
Ingalls & Snyder LLC (Asset Management)
7.74M
7.3%
-357.16K
-4.41%
Mar 31, 2025
Renaissance Technologies LLC
6.14M
5.79%
-55.57K
-0.90%
Mar 31, 2025
Baker (George Leonard Jr.)
5.31M
5.01%
--
--
Apr 17, 2025
Parallel Advisors, LLC
3.97M
3.75%
+142.78K
+3.73%
Mar 31, 2025
State Street Global Advisors (US)
3.40M
3.21%
-146.42K
-4.13%
Mar 31, 2025
Belanoff (Joseph K)
2.98M
2.81%
-40.35K
-1.34%
Apr 17, 2025
Wilson (James N)
2.35M
2.21%
+129.14K
+5.82%
Apr 17, 2025
Geode Capital Management, L.L.C.
2.26M
2.13%
+191.89K
+9.28%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
SPDR S&P Pharmaceuticals ETF
5.35%
Invesco S&P SmallCap Health Care ETF
5.17%
Pacer US Small Cap Cash Cows Growth Leaders ETF
4.73%
Formidable ETF
4.13%
Invesco Pharmaceuticals ETF
3.79%
First Trust NYSE Arca Biotechnology Index Fund
3.55%
iShares U.S. Pharmaceuticals ETF
3.46%
Invesco S&P SmallCap Momentum ETF
3.09%
Invesco S&P SmallCap Quality ETF
2.96%
Invesco S&P SmallCap 600 Pure Growth ETF
1.9%
View more
SPDR S&P Pharmaceuticals ETF
Proportion5.35%
Invesco S&P SmallCap Health Care ETF
Proportion5.17%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion4.73%
Formidable ETF
Proportion4.13%
Invesco Pharmaceuticals ETF
Proportion3.79%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.55%
iShares U.S. Pharmaceuticals ETF
Proportion3.46%
Invesco S&P SmallCap Momentum ETF
Proportion3.09%
Invesco S&P SmallCap Quality ETF
Proportion2.96%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.9%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
